BETA-TT8 Eyedropper Gel

BETA-TT8 is being developed as a breakthrough eyedropper treatment of intra-ocular inflammation (inflammatory conditions within the eyeball) including wet age-related macular degeneration (wet AMD), diabetic retinopathies and uveitis.

BETA platform drugs display a potent and comprehensive anti-inflammatory action through down-regulation of multiple genes responsible for angiogenesis (network of abnormal-shaped and leaky blood vessels), inflammatory cytokines, and immune cell-attracting chemokines.

The initial therapeutic indication being pursued is wet AMD, the main cause of vision loss in the older population.

BETA-TT8 is a small molecule that readily crosses the mammalian cornea to reach back of eye at high drug levels.

The primary benefits Filamon sees for BETA-TT8 Eyedropper Gel versus current treatment options are:

• Better control over the three symptoms causing vision loss – pathological angiogenesis, oedema, fibrosis (scarring).
• The prospect of a more durable therapeutic effect from blocking the underlying chronic, low-grade inflammatory process.
• The convenience of self-administered treatment at home.
• The avoidance of side-effects associated with intravitreal (eyeball) injections.